Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecast
SUPN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 4 analysts
- Price target
- $60.50 average of analyst targets
- Upside to target
- +59.7% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $0.66
- 52-week range
- $37.88 – $57.00
SUPN analyst ratings
4 analystsNumber of analysts at each rating.
SUPN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
SUPN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.56 | $0.49 | $0.62 | $0.61 | −8.7% | 2 |
| Current fiscal year (2026) | $2.54 | $2.42 | $2.65 | $2.40 | +5.8% | 2 |
| Next fiscal year (2027) | $4.30 | $4.06 | $4.55 | $2.54 | +69.8% | 2 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
SUPN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $221.1M | $219.5M | $223.7M | +15.1% | 3 |
| Current fiscal year (2026) | $884.0M | $874.0M | $890.0M | +22.9% | 3 |
| Next fiscal year (2027) | $1.36B | $993.4M | $2.42B | +54.4% | 4 |
SUPN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
SUPN revenue: reported and forecast
SUPN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.66 | $0.61 | $0.61 | $0.61 | $0.56 | −16.3% | 0 up · 2 down |
| Current fiscal year (2026) | $2.49 | $2.56 | $2.56 | $2.56 | $2.54 | +1.9% | 1 up · 1 down |
| Next fiscal year (2027) | $4.34 | $4.46 | $4.46 | $4.46 | $4.30 | −0.9% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
SUPN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; SUPN beat in 9 of 12.
What analysts expect from SUPN
4 analysts cover Supernus Pharmaceuticals; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $60.50, 59.7% above the latest close of $37.88. Analysts expect earnings of $2.54 per share for 2026, +5.8% from a year earlier. For 2027 the average estimate is $4.30 per share on revenue of $1.4 billion. Supernus Pharmaceuticals beat the EPS estimate in 9 of the last 12 quarters.
Related: SUPN income statement, SUPN key metrics, SUPN chart. See the SUPN stock overview for the latest quote and news.
SUPN forecast FAQ
What is Supernus Pharmaceuticals's price target?
The average analyst price target for Supernus Pharmaceuticals is $60.50, 59.7% above the latest close of $37.88.
Is Supernus Pharmaceuticals a buy, hold or sell?
Of 4 analysts covering Supernus Pharmaceuticals, 3 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Supernus Pharmaceuticals's EPS forecast?
Analysts forecast $2.54 per share for 2026 (range $2.42 to $2.65); for 2027 the estimate is $4.30.
What is Supernus Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $884.0 million, growth of 22.9%; for 2027 it is $1.4 billion.
When does Supernus Pharmaceuticals report earnings?
Supernus Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026 before the market opens; the EPS estimate is $0.66.
Does Supernus Pharmaceuticals usually beat earnings estimates?
Supernus Pharmaceuticals reported EPS at or above the analyst estimate in 9 of the last 12 quarters.